C. difficile 위험도


Mild or moderate CAPAECB320 mg PO q24h x5-7d320 mg PO q24h x5d

Safety and efficacy in pediatric patients <18y of age have not been established

No dose adjustment

CrCl >40CrCl ≤40CAPDHDCRRTNo dose adjustment160 mg PO q24h160 mg PO q24h160 mg q24h (give dialysis day dose after dialysis)No data

General Information

  • A fluoroquinolone bactericidal drug with a wide-spectrum of activity against Gram-negative and Gram-positive microorganisms

  • Acute bacterial exacerbation of chronic bronchitis

  • Community-acquired pneumonia

Black Box Warning:

  • Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions.

  • Reserve use of gemifloxacin mesylate for patients with no alternative treatment options for acute bacterial exacerbation of chronic bronchitis.

  • Avoid in patients with known history of myasthenia gravis.

Monitor fever, CBC, symptomatic improvement.


  • Rash

  • Abdominal pain

  • Diarrhea

  • Nausea

  • Vomiting

  • Headache

  • Dizziness


  • Aortic aneurysm

  • Prolonged QT interval

  • Hypoglycemia

  • Myasthenia gravis

  • Rupture of tendon

  • Tendinitis

  • Neurological symptoms

  • Psychiatric symptoms


  • QT interval prolonging drugs

Multiple drug-drug interactions

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 7 hours


  • Increased risk of QT interval prolongation in patients with ongoing proarrhythmic conditions.

  • Discotninue if hypersensitivity reactions, neurologic effects, and toxic psychosis occur.

  • Discontinue therapy at first sign of tendon pain, swelling, inflammation, or rupture.

  • Sensory or sensorimotor axonal polyneuropathy that may be irreversible has been reported; discontinue if symptoms occur.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.